Compare Burlington Stores Inc (BURL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Burlington Stores Inc vs Mesoblast Limited — how do they compare? Burlington Stores Inc trades at $352.82 (market cap $22.59B), while Mesoblast Limited trades at $16.87 (market cap $2.21B). The key difference: Burlington Stores Inc is far larger — about 10.2× Mesoblast Limited's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| BURL | MESO | |
|---|---|---|
Market Cap | $22.59B | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $372.19 | $20.96 |
52-Week Low | $242.43 | $12.88 |
Enterprise Value | $27.71B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $353.4, down 4.87% over 24 hours but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding expectations. Revenue grew to $10.63 billion in 2025, and the smaller-store strategy is boosting sales productivity. Analyst consensus is overwhelmingly positive, with 94% buy ratings and a $367 price target.
Outlook remains favorable due to consistent earnings outperformance and growth initiatives, though risks include high valuation multiples and competitive retail pressures. The stock offers upside potential aligned with analyst targets, but investors should monitor execution on expansion and margin sustainability.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
